Surrogate Wnts

The wide applicability of Surrozen Inc.'s regenerative medicine discovery platform persuaded The Column Group to lead its tranched series A round, which closed at $33 million on Feb. 15. The VC led the round with a $30 million commitment, joined by Stanford University and undisclosed individuals.

Surrozen is developing wingless-type MMTV integration site (Wnt) pathway agonists for undisclosed indications. ...